178 related articles for article (PubMed ID: 36509171)
1. Rapid Quantitation of Four Nitrosamine Impurities in Angiotensin Receptor Blocker Drug Substances.
Zhang J; Selaya SD; Shakleya D; Mohammad A; Faustino PJ
J Pharm Sci; 2023 May; 112(5):1246-1254. PubMed ID: 36509171
[TBL] [Abstract][Full Text] [Related]
2. A Multi-Analyte LC-MS/MS Method for Determination and Quantification of Six Nitrosamine Impurities in Sartans like Azilsartan, Valsartan, Telmisartan, Olmesartan, Losartan and Irbesartan.
Gopireddy RR; Maruthapillai A; Mahapatra S
J Chromatogr Sci; 2024 Feb; 62(2):147-167. PubMed ID: 35830866
[TBL] [Abstract][Full Text] [Related]
3. Investigation of Carcinogenic Impurities of N-Nitrosamines in Sartan Pharmaceutical Products Marketed in Brazil: Development and Validation of Method Based on High-Performance Liquid Chromatography-Tandem Mass Spectrometry.
Monteiro MA; de Lima PC; Novotny TS; Santana DS; Lima MED; Dantas ASCL; Ferreira LODS; de Souza MN; Maranho RLDN; Ochs SM
J Pharm Sci; 2023 May; 112(5):1305-1314. PubMed ID: 36657719
[TBL] [Abstract][Full Text] [Related]
4. A GC-MS/MS Method for Trace Level Quantification of Six Nitrosamine Impurities (NDMA, NDEA, NEIPA, NDIPA, NDPA, and NDBA) in Commercially Used Organic Solvents: Dichloromethane, Ethyl Acetate, Toluene, and O-xylene.
Kosuri ER; Bhanti M; Jaywant MA; Han M; Wang X; Obeng M
J Pharm Sci; 2023 May; 112(5):1225-1230. PubMed ID: 36462706
[TBL] [Abstract][Full Text] [Related]
5. An update on the current status and prospects of nitrosation pathways and possible root causes of nitrosamine formation in various pharmaceuticals.
Wichitnithad W; Nantaphol S; Noppakhunsomboon K; Rojsitthisak P
Saudi Pharm J; 2023 Feb; 31(2):295-311. PubMed ID: 36942272
[TBL] [Abstract][Full Text] [Related]
6. Genotoxicity evaluation of nitrosamine impurities using human TK6 cells transduced with cytochrome P450s.
Li X; He X; Le Y; Guo X; Bryant MS; Atrakchi AH; McGovern TJ; Davis-Bruno KL; Keire DA; Heflich RH; Mei N
Arch Toxicol; 2022 Nov; 96(11):3077-3089. PubMed ID: 35882637
[TBL] [Abstract][Full Text] [Related]
7. Simultaneous detection of nitrosamines and other sartan-related impurities in active pharmaceutical ingredients by supercritical fluid chromatography.
Schmidtsdorff S; Schmidt AH
J Pharm Biomed Anal; 2019 Sep; 174():151-160. PubMed ID: 31174128
[TBL] [Abstract][Full Text] [Related]
8. Nitrosamine Impurities in Pharmaceuticals: An Empirical Review of their Detection, Mechanisms, and Regulatory Approaches.
Bhirud D; Agrawal G; Shah H; Patel A; Palkar MB; Bhattacharya S; Prajapati BG
Curr Top Med Chem; 2024; 24(6):503-522. PubMed ID: 38321910
[TBL] [Abstract][Full Text] [Related]
9. Lesson Learnt from Recall of Valsartan and Other Angiotensin II Receptor Blocker Drugs Containing NDMA and NDEA Impurities.
Charoo NA; Ali AA; Buha SK; Rahman Z
AAPS PharmSciTech; 2019 Apr; 20(5):166. PubMed ID: 30989447
[TBL] [Abstract][Full Text] [Related]
10. The contamination of valsartan and other sartans, part 1: New findings.
Sörgel F; Kinzig M; Abdel-Tawab M; Bidmon C; Schreiber A; Ermel S; Wohlfart J; Besa A; Scherf-Clavel O; Holzgrabe U
J Pharm Biomed Anal; 2019 Aug; 172():395-405. PubMed ID: 31122801
[TBL] [Abstract][Full Text] [Related]
11. Neoplasm Reports in Food and Drug Administration Adverse Event Reporting System Following Angiotensin Receptor Blocker Recalls.
Cohen Sedgh R; Moon J; Jackevicius CA
Circ Cardiovasc Qual Outcomes; 2021 Aug; 14(8):e007476. PubMed ID: 34380327
[TBL] [Abstract][Full Text] [Related]
12. A collaborative study of the impact of N-nitrosamines presence and ARB recall on ARB utilization - results from IQVIA™ Disease Analyzer Germany.
Hedenmalm K; Quinten C; Kurz X; Bradley M; Lee H; Eworuke E
Eur J Clin Pharmacol; 2023 Jun; 79(6):849-858. PubMed ID: 37095262
[TBL] [Abstract][Full Text] [Related]
13. Development of a Sensitive Headspace Gas Chromatography-Mass Spectrometry Method for the Simultaneous Determination of Nitrosamines in Losartan Active Pharmaceutical Ingredients.
Wichitnithad W; Sudtanon O; Srisunak P; Cheewatanakornkool K; Nantaphol S; Rojsitthisak P
ACS Omega; 2021 Apr; 6(16):11048-11058. PubMed ID: 34056258
[TBL] [Abstract][Full Text] [Related]
14. Development of a sensitive LC-APCI-MS/MS method for simultaneous determination of eleven nitrosamines in valsartan and irbesartan with a simple extraction approach.
Mavis ME; Goksu Gursu G; Ular Cagatay N
J Chromatogr B Analyt Technol Biomed Life Sci; 2023 Feb; 1216():123593. PubMed ID: 36669257
[TBL] [Abstract][Full Text] [Related]
15. The contamination of valsartan and other sartans, Part 2: Untargeted screening reveals contamination with amides additionally to known nitrosamine impurities.
Scherf-Clavel O; Kinzig M; Besa A; Schreiber A; Bidmon C; Abdel-Tawab M; Wohlfart J; Sörgel F; Holzgrabe U
J Pharm Biomed Anal; 2019 Aug; 172():278-284. PubMed ID: 31078064
[TBL] [Abstract][Full Text] [Related]
16. Genotoxicity assessment of eight nitrosamines using 2D and 3D HepaRG cell models.
Seo JE; Yu JZ; Xu H; Li X; Atrakchi AH; McGovern TJ; Bruno KLD; Mei N; Heflich RH; Guo X
Arch Toxicol; 2023 Oct; 97(10):2785-2798. PubMed ID: 37486449
[TBL] [Abstract][Full Text] [Related]
17. Regulatory Experiences with Root Causes and Risk Factors for Nitrosamine Impurities in Pharmaceuticals.
Horne S; Vera MD; Nagavelli LR; Sayeed VA; Heckman L; Johnson D; Berger D; Yip YY; Krahn CL; Sizukusa LO; Rocha NFM; Bream RN; Ludwig J; Keire DA; Condran G
J Pharm Sci; 2023 May; 112(5):1166-1182. PubMed ID: 36599405
[TBL] [Abstract][Full Text] [Related]
18. Valsartan, Losartan and Irbesartan use in the USA, UK, Canada and Denmark after the nitrosamine recalls: a descriptive cohort study.
Eworuke E; Shinde M; Hou L; Paterson MJ; Jensen PB; Maro JC; Rai A; Scarnecchia D; Pennap D; Woronow D; Ghosh RE; Welburn S; Pottegard A; Platt RW; Lee H; Bradley MC
BMJ Open; 2023 Apr; 13(4):e070985. PubMed ID: 37068898
[TBL] [Abstract][Full Text] [Related]
19. A Cautionary Tale: Quantitative LC-HRMS Analytical Procedures for the Analysis of N-Nitrosodimethylamine in Metformin.
Yang J; Marzan TA; Ye W; Sommers CD; Rodriguez JD; Keire DA
AAPS J; 2020 Jul; 22(4):89. PubMed ID: 32613429
[TBL] [Abstract][Full Text] [Related]
20. Simultaneous Estimation of Six Nitrosamine Impurities in Valsartan Using Liquid Chromatographic Method.
Bodiwala KB; Panchal BG; Savale SS; Dave JB; Sureja DK; Dhameliya TM; Chhabria MT
J AOAC Int; 2022 Feb; 105(1):1-10. PubMed ID: 34338773
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
